Form 4: Bristol-Myers Squibb Exec's Routine Stock Transactions

Bristol-Myers Squibb's EVP, General Counsel, Cari Gallman, reported the acquisition of common stock through RSU vesting and subsequent tax-related share disposition.

Summary

• Cari Gallman, Executive Vice President and General Counsel of Bristol-Myers Squibb Company, reported changes in beneficial ownership on October 6, 2025.
• On October 2, 2025, Gallman acquired 4,558 shares of common stock with a $0.10 par value, resulting from the vesting of Restricted Stock Units (RSUs).
• Concurrently, 2,332 shares of common stock were disposed of at a price of $45.73 per share to cover tax obligations associated with the RSU vesting.
• Following these transactions, Gallman directly holds 11,066 shares of Bristol-Myers Squibb common stock.
• Gallman also beneficially owns 4,559 Restricted Stock Units, which are exercisable on October 2, 2026.
• The Restricted Stock Units vest in three equal installments, with the first installment having occurred on October 2, 2024.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing reports routine executive compensation transactions. The acquisition of shares through RSU vesting is a positive sign of executive equity ownership, though partially offset by tax-related sales.

Positives

• EVP, General Counsel Cari Gallman acquired 4,558 shares of common stock, indicating continued equity ownership and alignment with shareholder interests.
• The acquisition stems from the vesting of Restricted Stock Units, a common form of performance-based executive compensation.

Negatives

• 2,332 shares were disposed of to cover tax liabilities, which is a standard practice but reduces the net shares held by the executive.

Future Outlook

The filing indicates future vesting of RSUs, with the third and final installment expected to vest on October 2, 2026.

Industry Context

This is a routine insider transaction filing, common across all publicly traded companies, reflecting executive compensation practices rather than specific industry trends.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting executive stock transactions. The RSU vesting and subsequent tax-related sale are common practices for executive compensation in large pharmaceutical companies like Bristol-Myers Squibb and are consistent with industry norms for managing equity awards.

Stakeholder Impact

• Shareholders: Increased direct ownership by a key executive (net of tax sales) aligns executive interests with shareholder value.
• Employees: Reflects standard executive compensation practices.

Next Steps

• Future vesting of remaining Restricted Stock Units, with the next installment on October 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the vesting of Restricted Stock Units and subsequent tax-related share sales. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal any significant positive or negative shifts for Bristol-Myers Squibb's stock.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Cari Gallman, Common Stock, Share Ownership